Viravaxx Is A Drug Development Company Dedicated To Hepatitis B Vaccine Development With A Lead Vaccine Candidatevvx001Currently In Phase Ii Clinical Trials Aec Interim Data Confirm That Vvx001 Induces A Pres Specific Igg Antibody Response In Vaccine Naa Ve Adults And In Chronically Infected Patients Aec Abstracts Presenting Interim Data Were Recently Accepted For Publication At The American Association For The Study Of Liver Diseasesaasldand Hepdartaec Viravaxx Works With A Board Of International Renowned Hepatologists Including Anna Lokfabien Zoulimflorian Van Ba Mmelpatrick Kennedy And Peter Ferenci
